Literature DB >> 35471039

Reply to Shapiro, "Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing Enterobacterales".

Juan Carlos Vázquez-Ucha1, Cristina Lasarte-Monterrubio1, Paula Guijarro-Sánchez1, Marina Oviaño1, Laura Álvarez-Fraga1, Isaac Alonso-García1, Jorge Arca-Suárez1, German Bou1, Alejandro Beceiro1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35471039      PMCID： PMC9112983          DOI： 10.1128/aac.00353-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


× No keyword cloud information.
  8 in total

1.  Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam-β-Lactamase Inhibitor Combination.

Authors:  Krisztina M Papp-Wallace; Christopher R Bethel; Jocelyne Caillon; Melissa D Barnes; Gilles Potel; Saralee Bajaksouzian; Joseph D Rutter; Amokrane Reghal; Stuart Shapiro; Magdalena A Taracila; Michael R Jacobs; Robert A Bonomo; Cédric Jacqueline
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales.

Authors:  Juan Carlos Vázquez-Ucha; Cristina Lasarte-Monterrubio; Paula Guijarro-Sánchez; German Bou; Alejandro Beceiro; Marina Oviaño; Laura Álvarez-Fraga; Isaac Alonso-García; Jorge Arca-Suárez
Journal:  Antimicrob Agents Chemother       Date:  2021-11-22       Impact factor: 5.938

3.  Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing Enterobacterales.

Authors:  Stuart Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2022-04-26       Impact factor: 5.938

4.  An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.

Authors:  Burcu Isler; Patrick Harris; Adam G Stewart; David L Paterson
Journal:  J Antimicrob Chemother       Date:  2021-02-11       Impact factor: 5.790

5.  Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.

Authors:  Matthew E Falagas; Giannoula S Tansarli; Drosos E Karageorgopoulos; Konstantinos Z Vardakas
Journal:  Emerg Infect Dis       Date:  2014-07       Impact factor: 6.883

6.  In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014-2015.

Authors:  Ian Morrissey; Sophie Magnet; Stephen Hawser; Stuart Shapiro; Philipp Knechtle
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

7.  In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020.

Authors:  Yu-Lin Lee; Wen-Chien Ko; Wen-Sen Lee; Po-Liang Lu; Yen-Hsu Chen; Shu-Hsing Cheng; Min-Chi Lu; Chi-Ying Lin; Ting-Shu Wu; Muh-Yong Yen; Lih-Shinn Wang; Chang-Pan Liu; Pei-Lan Shao; Zhi-Yuan Shi; Yao-Shen Chen; Fu-Der Wang; Shu-Hui Tseng; Chao-Nan Lin; Yu-Hui Chen; Wang-Huei Sheng; Chun-Ming Lee; Hung-Jen Tang; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2021-06-21       Impact factor: 5.283

8.  In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae.

Authors:  Lucas Tselepis; Gareth W Langley; Ali F Aboklaish; Emma Widlake; Dana E Jackson; Timothy R Walsh; Chris J Schofield; Jürgen Brem; Jonathan M Tyrrell
Journal:  Int J Antimicrob Agents       Date:  2020-02-18       Impact factor: 5.283
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.